Published in Blood on August 26, 2013
An European Platform for Translational Research in Myelodysplastic Syndromes | NCT04174547
GENOMED4ALL: Improving MDS Classification and Prognosis by AI | NCT04889729
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood (2015) 2.46
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood (2015) 1.75
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood (2014) 1.29
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int (2013) 1.21
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia (2014) 1.02
The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97
Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging (2014) 0.96
Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw (2015) 0.92
Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica (2014) 0.92
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res (2014) 0.90
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Mol Cell Biol (2015) 0.89
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia (2015) 0.88
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep (2015) 0.85
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia (2015) 0.84
Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol (2016) 0.84
Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality? Haematologica (2015) 0.82
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica (2016) 0.81
Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol (2015) 0.81
GFI1 as a novel prognostic and therapeutic factor for AML/MDS. Leukemia (2016) 0.80
Time-dependent changes in mortality and transformation risk in MDS. Blood (2016) 0.79
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica (2016) 0.79
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. Biol Blood Marrow Transplant (2014) 0.79
The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. Leukemia (2015) 0.78
High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. Haematologica (2015) 0.78
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. Mediterr J Hematol Infect Dis (2015) 0.78
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med (2016) 0.78
Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome. Oncotarget (2015) 0.77
Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis. PLoS Comput Biol (2014) 0.77
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist (2014) 0.77
Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clin Case Rep (2015) 0.76
Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia (2016) 0.76
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes. Anemia (2016) 0.76
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy. Stem Cells Cloning (2014) 0.75
Preleukemia: One name, many meanings. Leukemia (2016) 0.75
The indications for allogeneic stem cell transplantation in myeloid malignancies. Dtsch Arztebl Int (2015) 0.75
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. J Cancer Res Clin Oncol (2017) 0.75
Recent frustration and innovation in myelodysplastic syndrome. Haematologica (2016) 0.75
The Danish National Acute Leukemia Registry. Clin Epidemiol (2016) 0.75
Flying without a net in MDS. Blood (2013) 0.75
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Mediterr J Hematol Infect Dis (2017) 0.75
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden. Leukemia (2015) 0.75
Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights. Oncol Rev (2016) 0.75
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS One (2016) 0.75
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer (2016) 0.75
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant (2016) 0.75
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant (2016) 0.75
Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. Biomed Res Int (2015) 0.75
Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. Oncotarget (2016) 0.75
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leuk Res (2015) 0.75
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica (2016) 0.75
The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores. J Med Life (2014) 0.75
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol (2016) 0.75
Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. Haematologica (2014) 0.75
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med (2014) 0.75
Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia (2016) 0.75
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol (2017) 0.75
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget (2016) 0.75
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transplant (2016) 0.75
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transplant (2017) 0.75
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Ann Hematol (2017) 0.75
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia (2017) 0.75
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients. Int J Clin Oncol (2016) 0.75
Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. Mol Cytogenet (2017) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
A new system for grading recommendations in evidence based guidelines. BMJ (2001) 11.13
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood (2007) 9.82
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med (2005) 8.80
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care (1986) 7.26
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Telomere diseases. N Engl J Med (2009) 5.68
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood (2008) 4.41
European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica (2005) 4.34
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet (2011) 3.41
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica (2005) 3.24
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med (2004) 2.97
Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med (2005) 2.94
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol (2010) 2.93
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol (2003) 2.54
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
Iron in the heart. Etiology and clinical significance. Am J Med (1971) 2.40
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood (2007) 2.37
Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol (1995) 2.27
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia (2010) 2.23
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood (2002) 2.14
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol (2009) 2.04
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol (2009) 2.03
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med (1993) 2.02
Bone marrow transplantation in patients with thalassemia. N Engl J Med (1990) 1.99
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol (2008) 1.99
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med (2008) 1.97
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood (2007) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (2002) 1.89
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol (2005) 1.85
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol (2008) 1.84
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol (2003) 1.81
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol (2002) 1.80
Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest (2012) 1.79
Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood (2008) 1.78
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol (2012) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant (2012) 1.67
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol (2012) 3.81
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med (2003) 3.64
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica (2005) 3.24
Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med (2010) 3.20
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood (2002) 2.71
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood (2008) 2.55
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol (2003) 2.54
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 2.49
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A (2007) 2.39
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood (2007) 2.37
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res (2013) 2.24